© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
April 11, 2021
TAS-117 showed limited clinical efficacy in treating patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.
February 14, 2021
Investigational agent belzutifan plus cabozantinib was able to control tumor growth in most patients with advanced clear cell renal cell carcinoma in a phase 2 trial.
December 05, 2020
Treatment with momelotinib improved overall survival and sustained efficacy outcomes in patients with intermediate- or high-risk myelofibrosis.
September 21, 2020
Based on these data, researchers indicated that adjuvant osimertinib would be an effective and practice-changing treatment in this setting.
May 29, 2020
Women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumor with the expectation of a survival benefit, according to results from the ECOG-ACRIN E2108 trial.